This means that these immunocytokines that specifically target cancer cells have a wider therapeutic window than unconjugated IL-2 (Chen et al. 2016; Christ et al. 2001; Dougan et al. 2018; Gillies et al. 2005; Runbeck et al. 2021; Sugimoto et al. 2014; Ziffels et al. 2019). The gene discussed is IL2; the disease is cancer.